Cardurion is developing therapeutics targeting PDE9 and CaMKII pathways to treat heart failure and various cardiovascular diseases. Their approach aims to provide effective treatment options for chronic heart failure and rare arrhythmias, addressing significant unmet medical needs in cardiovascular care.
Funding
$621.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart failure and cardiovascular diseases present significant unmet medical needs, with current treatments often failing to adequately address the underlying mechanisms of disease progression. Existing therapies may not effectively target key signaling pathways involved in cardiac dysfunction, leading to suboptimal outcomes for patients with chronic heart failure and arrhythmias.
Solution
Cardurion Pharmaceuticals is developing novel therapeutics that target PDE9 and CaMKII, two critical signaling pathways implicated in heart failure and various cardiovascular diseases. By selectively inhibiting PDE9, Cardurion aims to enhance cardiac function and improve outcomes for patients with both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Their CaMKII inhibitor represents a first-in-class approach to address calcium dysregulation in cardiac cells, offering potential benefits for patients with rare arrhythmias like catecholaminergic polymorphic ventricular tachycardia (CPVT), as well as more common cardiovascular conditions such as atrial fibrillation. Cardurion's approach involves identifying new targets, developing novel drug candidates, and employing adaptive trial designs and precision medicine strategies to accelerate the development of effective cardiovascular therapies.
Target Audience
The primary target audience includes patients suffering from heart failure (both HFrEF and HFpEF), rare arrhythmias such as CPVT, and other cardiovascular diseases, as well as healthcare providers specializing in cardiology.
Features
- Selective PDE9 inhibitors designed to improve cardiac function in HFrEF and HFpEF patients
- First-in-class CaMKII inhibitors to address calcium dysregulation in cardiac diseases
- Clinical programs focused on heart failure, CPVT, and atrial fibrillation
- Adaptive trial designs to optimize clinical development and accelerate regulatory approval
- Precision medicine approaches to identify patient populations most likely to benefit from Cardurion's therapies